Use of discrete event simulation (DEM) to evaluate the clinical practices in neovascular age-related macular degeneration

SCHLOTTMANN P; LUNA J.D; PALMA SD; REAL J.P

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Lugar: Rockville, MD 20852; Año: 2017 vol. 58 p. 428 - 428

0146-0404

urpose:To evaluate the outcomes and direct medical cost of different regimens treatment in managing nAMD.Methods:We developed a discrete event simulation model that reproducing the long-term evolution of 5000 patients with nAMD. The model allows calculation the cost-effectiveness of treatment of AMD with Ranibizumab in two different therapeutic regimens: pro re nata (PRN) and Treat and Extend (TAE). Ranibizumab at the price of Lucentis (U$2000) and Ranibizumab at the price of Accentix (U$380). Data on effectiveness, rate of visual loss without treatment,the vision-related quality of life, time with VEGF suppression and time to functional recurrence were identified through a systematic literature searches. Time horizons were 10 years. A third-party-payer perspective was employed. A discount rate of 3% per annum was considered for both costs and outcomes benefits.Result: Over ten years of simulated treatment show us that the use of TAE scheme implies a higher number of intravitreal do